Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
CANbridge Pharmaceuticals Inc. ( (HK:1228) ) just unveiled an update.
CANbridge Pharmaceuticals Inc. announced its annual results for the year ended December 31, 2024, highlighting significant advancements in its drug pipeline and business operations. Key achievements include the commercial launch of Hunterase® and Livmarli® in China, with substantial patient identification and insurance coverage expansion. The company also reported positive trial results for CAN103 for Gaucher disease and received priority review status from the China NMPA. Organizational changes were noted, with new appointments to the audit and remuneration committees.
More about CANbridge Pharmaceuticals Inc.
CANbridge Pharmaceuticals Inc. is a biopharmaceutical company incorporated in the Cayman Islands, focusing on the development and commercialization of innovative therapies for rare diseases and targeted oncology. The company has a significant presence in China, where it has launched several products and is expanding its market reach.
YTD Price Performance: 21.05%
Average Trading Volume: 1,082,896
Technical Sentiment Signal: Buy
Current Market Cap: HK$68.4M
For detailed information about 1228 stock, go to TipRanks’ Stock Analysis page.